Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Inclusion Criteria

• •Histologic or cytologic diagnosis of stage III non-small cell lung cancer; patients will need to meet the following criteria for stage IIIA or IIIB diagnosis:
• •* IIIA
• •* Histologic or cytologic diagnosis of ipsilateral mediastinal lymph node involvement, or
• •* Tumors greater than 7 cm or with chest wall invasion, or involvement of one of the following diaphragm, phrenic nerve, mediastinal pleura or parietal pericardium with hilar or mediastinal lymph node involvement
• •* More than one mediastinal lymph node enlarged on computed tomography (CT) scan and the same lymph nodes positive on positron emission tomography (PET) scans or
• •* Paralyzed left vocal cord with separate lung primary distinct from the aorto-pulmonary lymph nodes on the CT scan
• •* IIIB
• •* Histologic or cytologic diagnosis of N3 lymph node involvement; or
• •* Enlarged N3 lymph nodes on CT scan that are positive on PET scan as well; patient must not have extension of lymph node involvement to cervical lymph nodes other than supraclavicular lymph nodes; or
• •* Right sided primary with left vocal cord paralysis; or
• •* Evidence of tumor extension into the mediastinum and/or mediastinal structures either at the time of mediastinoscopy, bronchoscopy or on CT scans
• •* Patients with a nodules in the same lung but no other areas of involvement
• •* Patients with prior surgically resected stage I NSCLC who did not receive any adjuvant therapy, who now have stage IIIA or B NSCLC will be eligible
• •Southwestern Oncology Group (SWOG) performance status 0 or 1
• •Absolute neutrophil count of \> 1.5 x 10\^9/L
• •Platelet count \> 100,000 x 10\^9/L
• •Serum creatinine =\< 1.5 times the institutional upper limit of normal (ULN)
• •Calculated creatinine clearance (Cockcroft-Gault formula) of \>= 45mL/min
• •Serum bilirubin \> ULN
• •Transaminases (serum glutamic oxaloacetic transaminase \[SGOT\] and/or serum glutamate pyruvate transaminase \[SGPT\]) \> 1.5 times institutional ULN
• •Alkaline phosphatase \>= 2.5 times ULN
• •Forced expiratory volume in one second (FEV1) of \>= 1 liter and diffusion capacity of carbon monoxide (DLCO) \>= 40% of predicted
• •Patient should undergo brain imaging (CT scan or magnetic resonance imaging \[MRI \]) to rule out brain metastases
• •Signed informed consent that details the investigational nature of the study according to institutional and federal guidelines
• •Registered with Clinical Trials Office at Karmanos Cancer Institute/Wayne State University